• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jurbhealthspringer.comThis journalToc AlertsSubmit OnlineOpen ChoiceThis journal
J Urban Health. Dec 1999; 76(4): 461–467.
PMCID: PMC3456694

Incentives and accessibility: A pilot study to promote adherence to TB prophylaxis in a high-risk community

Abstract

Setting

A community-based directly observed preventive therapy (DOPT) program for treatment of latent tuberculosis infection among injection drug users (IDUs) in an innercity neighborhood.

Objective

To test adherence to a 6-month course of DOPT using cash incentives and an easily accessible neighborhood location.

Design

Street-recruited IDUs (N=205) were screened forMycobacterium tuberculosis (TB) infection using the Mantoux test and two controls. Subjects who had a purified protein derivative (PPD) reaction of ≥5 mm, were anergic, or had a history of a positive PPD received clinical evaluation at a community field site, provided in collaboration with the San Francisco Department of Public Health Tuberculosis Clinic. Twenty-eight subjects were considered appropriate candidates for prophylaxis with isoniazid, and 27 enrolled in the pilot study. Participants received twice-weekly DOPT at a community satellite office, with a $10 cash incentive at each visit.

Results

The 6-month (26-week) regimen was completed by 24/27 (89%) participants. The median time to treatment completion was 27 weeks (range 26 to 34 weeks). The median proportion of dosing days attended in 6 months was 96%.

Conclusion

Community-based DOPT using cash incentives resulted in high levels of adherence and treatment completion among drug users.

Full Text

The Full Text of this article is available as a PDF (367K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Centers for Disease Control and Prevention Prevention and control of tuberculosis in US communities with at-risk minorities; and among homeless persons: recommendations of the Advisory Council for the Elimination of Tuberculosis. Morb Mortal Wkly Rep. 1992;41(RR5):1–23. [PubMed]
2. Centers for Disease Control and Prevention The use of preventive therapy for tuberculosis infection in the United States: recommendations of the Advisory Committee for the Elimination of Tuberculosis. Morb Mortal Wkly Rep. 1990;39(RR-8):9–12.
3. Gourevitch MN, Alcabes P, Wasserman WC, Arno PS. Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis. Int J Tuberc Lung Dis. 1998;2(7):531–540. [PubMed]
4. Daly CL, Hahn HA, Moss AR, Hopewell PC, Schecter GF. Incidence of tuberculosis in injection drug users in San Francisco: impact of anergy. Am J Respir Crit Care Med. 1998;157:19–22. [PubMed]
5. Snyder DC, Paz EA, Mohle-Boetani J, Black R, Fallstad R, Chin DP. Tuberculosis prevention in methadone maintenance clinics: effectiveness and cost-effectiveness. Am J Respir Crit Care Med. 1999;160:178–185. [PubMed]
6. Smirnoff M, Goldberg R, Indyk L, Adler JJ. Directly observed therapy in an inner city hospital. Int J Tuberc Lung Dis. 1998;2(2):134–139. [PubMed]
7. Giuffrida A, Torgerson D. Should we pay the patient? Review of financial incentives to enhance patient compliance. BMJ. 1997;315:703–707. [PMC free article] [PubMed]
8. Volmink J, Garner P. Systematic review of randomised controlled trials of strategies to promote adherence to tuberculosis treatment. BMJ. 1997;315:1403–1406. [PMC free article] [PubMed]
9. Malotte CK, Rhodes F, Mais K. Tuberculosis screening and compliance with return for skin test reading among active drug users. Am J Public Health. 1998;88:792–796. [PMC free article] [PubMed]
10. Pilote L, Tulsky J, Zolopa A, Hahn J, Schecter G, Moss A. Tuberculosis prophylaxis in the homeless: a trial to improve adherence to referral. Arch Intern Med. 1996;156:161–165. doi: 10.1001/archinte.156.2.161. [PubMed] [Cross Ref]
11. Malotte CK, Hollingshead JR, Rhodes F. Monetary versus nonmonetary incentives for TB skin test reading among drug users. Am J Prev Med. 1999;16(3):182–188. doi: 10.1016/S0749-3797(98)00093-2. [PubMed] [Cross Ref]
12. Watters JK. Trends in risk behavior and HIV seroprevalence among injecting drug users in San Francisco, 1986–1992. J Acquir Immune Defic Syndr. 1994;7:1276–1281. [PubMed]
13. Watters JK, Biernacki P. Targeted sampling: options for the study of hidden populations. Soc Problems. 1989;36:416–430.
14. Lifson AR, Grant SM, Lorvick J, et al. Two-step tuberculin skin testing of injection drug users recruited from community-based settings. Int J Tuberc Lung Dis. 1997;1:128–134. [PubMed]
15. Lifson AR, Thompson S, Grant S, Hilk R, Lorvick J. Skin test anergy among injection drug users recruited from community settings. J Drug Issues. 1998;28(4):891–904.
16. Centers for Disease Control Purified protein derivative (PPD)-tuberculin anergy and HIV infection: guidelines for anergy testing and management of anergic persons at risk of tuberculosis. Morb Mortal Wkly Rep. 1991;40(RR-5):27–33. [PubMed]
17. Fitzgerald JM, Patrick DM, Strathdee S, et al. Use of incentives to increase compliance for TB screening in a population of intravenous drug users. Vancouver Injection Drug Use Study Group. Int J Tuberc Lung Dis. 1999;3:153–155. [PubMed]
18. Farmer P, Robin S, Ramilus S, Kim JY. Tuberculosis, poverty, and “compliance”: lessons from rural Haiti. Semin Respir Infect. 1991;6(4):254–260. [PubMed]
19. Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. JAMA. 1995;274:945–951. doi: 10.1001/jama.274.12.945. [PubMed] [Cross Ref]
20. Nazar-Stewart V, Nolan CM. Results of a directly observed intermittent isoniazid preventive therapy program in a shelter for homeless men. Am Rev Respir Dis. 1992;146:57–60. [PubMed]
21. Alcabes P, Vossenas P, Cohen R, et al. Compliance with isoniazid in jail. Am Rev Respir Dis. 1989;140:1194–1197. [PubMed]
22. Moriskey DE, Malotte CK, Choi P, et al. A patient education program to improve adherence rates with antituberculosis drug regimens. Health Ed Q. 1990;17(3):253–267. [PubMed]
23. Chaisson RE, Keruly JC, McAvinue S, Gallant JE, Moore RD. Effects of an incentive and education program on return rates for PPD test reading in patients with HIV infection. J Acquir Immune Dis Syndr. 1996;11:455–459. [PubMed]
24. Mangura BT, Passannante L, Reichman B. An incentive in tuberculosis preventive therapy for an inner city population. Int J Tuberc Lung Dis. 1997;1:576–578. [PubMed]
25. Schecter G. Supervised therapy in San Francisco. Clin Chest Med. 1997;18(1):165–168. doi: 10.1016/S0272-5231(05)70366-X. [PubMed] [Cross Ref]
26. El-Sadr W, Medard F, Barthaud V. Directly observed therapy for tuberculosis: the Harlem Hospital experience, 1993. Am J Public Health. 1996;86(8):1146–1148. [PMC free article] [PubMed]

Articles from Journal of Urban Health : Bulletin of the New York Academy of Medicine are provided here courtesy of New York Academy of Medicine

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...